文献速递前列腺癌

种系DNA修复缺陷型前列腺癌的治疗结局与肿瘤杂合性缺失

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
PubMed 文献 · Eur Urol · 2017-03-01

研究纳入319例转移性去势抵抗性前列腺癌(mCRPC)患者,对22个DNA修复基因进行种系靶向测序,并对种系有害突变患者检测血浆游离DNA。24例(7.5%)携带种系有害突变,BRCA2最常见(n=16)。同源重组相关基因突变患者(n=22)起始雄激素剥夺治疗(ADT)后至mCRPC的中位时间为11.8个月(95%CI 5.1-18.4),mCRPC一线雄激素受体(AR)靶向治疗的中位PSA进展时间为3.3个月(95%CI 2.7-3.9)。11例可评估种系BRCA2突变患者中10例在循环肿瘤DNA(ctDNA)中检出完整等位基因的体细胞缺失。

要点

  • 319例mCRPC中24例(7.5%)携带种系DNA修复基因有害突变,BRCA2突变16例。
  • 同源重组相关基因突变患者(n=22)起始ADT后至mCRPC的中位时间为11.8个月(95%CI 5.1-18.4)。
  • mCRPC一线AR靶向治疗的中位PSA进展时间为3.3个月(95%CI 2.7-3.9)。

核心结论

  • 携带种系DNA修复缺陷的mCRPC患者对AR靶向治疗反应减弱。
  • ctDNA中可稳定检出双等位基因缺失,提示该患者亚组可优先考虑利用DNA修复缺陷的疗法。

研究设计与样本

  • 招募319例mCRPC患者,对22个DNA修复基因进行种系靶向测序。
  • 对种系有害突变患者同时进行血浆游离DNA测序。
  • 采用Kaplan-Meier分析评估初始ADT及后续mCRPC治疗中的PSA应答与进展。

主要发现

  • 319例中24例(7.5%)携带种系有害突变,BRCA2(n=16)最常见。
  • 同源重组相关基因突变患者(n=22)起始ADT后至mCRPC的中位时间为11.8个月(95%CI 5.1-18.4)。
  • mCRPC一线AR靶向治疗的中位PSA进展时间为3.3个月(95%CI 2.7-3.9)。
  • 11例可评估种系BRCA2突变患者中10例在ctDNA中检出完整等位基因的体细胞缺失。

临床怎么用

  • 原文结论认为,携带种系DNA修复缺陷的mCRPC患者对AR靶向治疗反应减弱,并提示该亚组可优先考虑利用DNA修复缺陷的疗法。
  • 原文患者摘要指出,携带种系DNA修复缺陷的转移性前列腺癌患者对标准激素治疗反应差,但可通过血液检测优先考虑可能更有效的疗法。

局限性

  • 本研究缺乏用于比较临床结局的正式对照队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Germline mutations in DNA repair genes were recently reported in 8-12% of patients with metastatic castration-resistant prostate cancer (mCRPC). It is unknown whether these mutations associate with differential response to androgen receptor (AR)-directed therapy. OBJECTIVE: To determine the clinical response of mCRPC patients with germline DNA repair defects to AR-directed therapies and to establish whether biallelic DNA repair gene loss is detectable in matched circulating tumor DNA (ctDNA). DESIGN, SETTING, AND PARTICIPANTS: We recruited 319 mCRPC patients and performed targeted germline sequencing of 22 DNA repair genes. In patients with deleterious germline mutations, plasma cell-free DNA was also sequenced. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Prostate-specific antigen response and progression were assessed in relation to initial androgen deprivation therapy (ADT) and subsequent therapy for mCRPC using Kaplan-Meier analysis. RESULTS AND LIMITATIONS: Of the 319 patients, 24 (7.5%) had deleterious germline mutations, with BRCA2 (n=16) being the most frequent. Patients (n=22) with mutations in genes linked to homologous recombination were heterogeneous at initial presentation but, after starting ADT, progressed to mCRPC with a median time of 11.8 mo (95% confidence interval [CI] 5.1-18.4). The median time to prostate-specific antigen progression on first-line AR-targeted therapy in the mCRPC setting was 3.3 mo (95% CI 2.7-3.9). Ten out of 11 evaluable patients with germline BRCA2 mutations had somatic deletion of the intact allele in ctDNA. A limitation of this study is absence of a formal control cohort for comparison of clinical outcomes. CONCLUSIONS: Patients with mCRPC who have germline DNA repair defects exhibit attenuated responses to AR-targeted therapy. Biallelic gene loss was robustly detected in ctDNA, suggesting that this patient subset could be prioritized for therapies exploiting defective DNA repair using a liquid biopsy. PATIENT SUMMARY: Patients with metastatic prostate cancer and germline DNA repair defects exhibit a poor response to standard hormonal therapies, but may be prioritized for potentially more effective therapies using a blood test.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Annala M, Struss WJ, Warner EW, et al. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. Eur Urol. 2017. PMID: 28259476. doi:10.1016/j.eururo.2017.02.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。